01 Aug 2014
(MENAFN) A US biotech company pioneering tablets containing embedded microchips that can tell if patients have taken their medication said it has raised a further USD172 million, including funds from a firm part-owned by Abu Dhabi”s Mubadala Development Company, according to Arabian Business.
Privately held Proteus Digital Health, which is working with drugmakers including Novartis and Otsuka, said this week the funding was one of the biggest US private financings this year and the largest in the digital health sector and shows investor interest in its ingestible and wearable technology.
Proteus already has European and US approval for its “smart pill” technology system, in which a tiny sensor is embedded in a tablet and linked to a patch worn on the patient’s abdomen.
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
26 Jan 2026
BBK Enhances Autumn Fair 2026 Experience with Customized Rewards and Premium Services
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more